Evidence map›Paper›PMID 42020098›Full record

GuidelineESMO open2026

Uveal melanoma: ESMO-EURACAN Clinical Practice Guideline for diagnosis, treatment and follow-up.

S Piperno-Neumann, M Angi, P A Ascierto, J F Baurain, M C Burgmans, N Cassoux, S E Coupland, R Dendale, A Fortuna, L Gastaud and 22 more

Abstract readPractice Guideline
PubMed Full text at PMC Publisher
In one paragraph

Guideline in ESMO open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

32 authors.

S Piperno-NeumannDepartment of Medical Oncology, Institut Curie, Paris, France.
M AngiOcular Oncology Unit, Department of Surgical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
P A AsciertoUniversità degli Studi di Napoli Federico II, Napoli, Italy; Department of Melanoma, Cancer Immunotherapy and Developmental Therapeutics, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Italy.
J F BaurainInstitut Roi Albert II, Cliniques universitaires Saint-Luc, UCLouvain, Brussels, Belgium.
M C BurgmansDepartment of Radiology, Leiden University Medical Centre, Leiden, The Netherlands.
N CassouxDepartment of Ocular Oncology, Institut Curie, Université Paris Cité, Paris, France.
S E CouplandLiverpool Clinical Laboratories, Liverpool University Hospitals Foundation Trust, Liverpool, UK; Department of Eye and Vision Science, Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool, UK.
R DendaleDepartment of Radiation Oncology, Institut Curie, Paris, France.
A FortunaHospital Santa Maria - Centro Hospitalar Universitario de Lisboa Norte EPE, Lisbon, Portugal.
L GastaudDepartment of Onco-Hematology, Centre Antoine Lacassagne, Nice, France.
C Gutierrez-MiguelezDepartment of Radiation Oncology, Hospital del Mar, Barcelona, Spain; Department of Radiation Oncology, Institute Català d'Oncologia, Barcelona, Spain.
S HeegaardDepartment of Pathology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
M J JagerDepartment of Ophthalmology, Leiden University Medical Center, Leiden, The Netherlands.
E KapiteijnDepartment of Medical Oncology, Leiden University Medical Center, Leiden, The Netherlands.
U KeilholzCharité Comprehensive Cancer Center, Charité - Universitätsmedizin Berlin, Berlin, Germany; National Center for Tumor Diseases, NCT Berlin (a partnership between DKFZ, Charité - Universitätsmedizin Berlin, Berlin Institute of Health at Charité and Max Delbrück Center for Molecular Medicine), Berlin, Germany.
E KilicDepartment of Ophthalmology, Erasmus MC University Medical Center Rotterdam, Rotterdam, The Netherlands.
M MarinkovicDepartment of Ophthalmology, Leiden University Medical Center, Leiden, The Netherlands.
A MoulinOphthalmic Pathology Laboratory and Department of Ophthalmology, Jules Gonin Eye Hospital, Lausanne, Switzerland.
P NathanMount Vernon Cancer Centre, Northwood, UK.
S P PatelDepartments of Ophthalmology, Division of Medical Oncology, University of Colorado, Aurora, USA; Departments of Medicine, Division of Medical Oncology, University of Colorado, Aurora, USA.
A PicaProton Therapy Center, Paul Scherrer Institute, Villigen, Switzerland.
J M PiulatsDepartment of Medical Oncology, Institut Català d'Oncologia, Hospitalet de Llobregat, Barcelona, Spain.
B RyllMelanoma Patient Network Europe, Uppsala, Sweden.
J J SaccoDepartment of Eye and Vision Science, Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool, UK; The Clatterbridge Cancer Centre, Wirral, UK.
W SauerweinDepartment of Radiation Therapy, University Hospital Essen, Essen, Germany.
M SchlaakDepartment of Dermatology, Venereology and Allergology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
B StedmanDepartment of Interventional Radiology, University Hospital Southampton, Southampton, UK.
A ValenteChampalimaud Foundation, Lisbon, Portugal.
R M VerdijkDepartment of Pathology, Leiden University Medical Center, Leiden, The Netherlands; Department of Pathology, Section Ophthalmic Pathology, Erasmus MC University Medical Center Rotterdam, Rotterdam, The Netherlands.
C VerhoefDepartment of Surgery, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
O MichielinDepartment of Oncology, Geneva University Hospital, Geneva, Switzerland.
ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

guidelinemelanomarare cancertreatmentuveal

Identifiers

PMID42020098
PMCPMC13131131

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.